Individual Patient Compassionate Use of Crenolanib
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
AgeNot listed
SponsorArog Pharmaceuticals, Inc.
About this trial
Compassionate use of crenolanib for patients with serious life-threatening illness that have exhausted all available therapies used to treat the disease, with no other viable therapy options, who is not eligible for clinical trials. This program is designed to evaluate the requests on a patient by patient basis.
Patients must have documented evidence of a point mutation in position 842 in platelet derived growth factor receptor alpha (PDGFRA-D842V) or amplification of PDGFRA or internal tandem duplication within the FMS-like tyrosine kinase 3 (FLT3-ITD) or point mutations within the tyrosine kinase domain (TKD) of FLT3 (FLT3-TKD)
Eligibility criteria
Qualifiers
Subject must have a serious life threatening cancer with FLT3/PDGFRa mutation or PDGFRa amplification who has exhausted all other treatment options
Subject and their partner (if adults) must use 2 forms of contraception during study and for 3 months following last dose of study drug
Disqualifiers
Subject is eligible for enrollment in an ongoing clinical trial
Subject has any condition which, in the investigator's opinion makes the subject unsuitable for participation
Trial design
Treatments tested in this trial
- Crenolanib besylate
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov